Patent: 10,704,038
✉ Email this page to a colleague
Summary for Patent: 10,704,038
Title: | Therapeutic fusion proteins |
Abstract: | The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor. |
Inventor(s): | Chaddock; John (Abingdon, GB), Harper; Elaine (Abingdon, GB) |
Assignee: | IPSEN BIOINNOVATION LIMTIED (Abingdon, GB) |
Application Number: | 16/105,203 |
Patent Claims: | see list of patent claims |
Details for Patent 10,704,038
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2031-05-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |